Tocilizumab for Advanced Non‐Small‐Cell Lung Cancer With Concomitant Cachexia: An Observational Study
Tocilizumab demonstrated significant benefits in survival and various clinical parameters, including body weight, albumin, CRP, mGPS and symptom burden in patients with NSCLC and concurrent IL-6-elevated cachexia. Given the existing unmet medical need for effective interventions for cancer cachexia, tocilizumab may be considered as a potential treatment option.
Authors
- Minjiang Chen (ORCID: https://orcid.org/0000-0002-4040-6115)
- Mengzhao WANG
- Xiaoyan Si
- Yang Du
- Xiaoyan Liu (ORCID: https://orcid.org/0000-0002-1732-5923)
- Xiaotong Zhang (ORCID: https://orcid.org/0000-0001-8937-820X)
- Li Zhang (ORCID: https://orcid.org/0000-0002-8101-672X)
- Ruili Pan
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Journal of Cachexia Sarcopenia and Muscle
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1002/jcsm.13638
- Citations
- 22
- Primary Topic
- Nutrition and Health in Aging
- Type
- article
- Field-Weighted Citation Impact
- 7.18
Funders
- American Society of Clinical Oncology
- National University of Singapore
- Shanghai Jiao Tong University
- Peking Union Medical College Hospital
- Peking Union Medical College
- School of Medicine, Shanghai Jiao Tong University